We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Testosterone Linked to Higher Rate of Colon Cancer in Males

By LabMedica International staff writers
Posted on 22 Dec 2014
Results of experiments carried out with two established animal colon cancer models indicated that the male hormone testosterone was responsible for males having a greater likelihood of developing the disease.

It has been recognized recently that men develop colonic adenomas and carcinomas at an earlier age and at a higher rate than women. More...
This sex susceptibility also occurs in the ApcPirc/+ (Pirc) rat model of early colonic cancer, with male Pirc rats developing twice as many adenomas as females. The ApcMin/+ mouse also shows enhanced male susceptibility to cancer formation, but only in the colon.

Investigators at the University of Missouri (Columbia, USA) worked with these two rodent populations to determine whether the males' natural high levels of testosterone or the lack of female hormones was related to the increased development of colon cancer.

They reported in the November 3, 2014, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that removing testosterone from the rodents by castration caused colon cancer rates to decrease dramatically. Restoration of testosterone by dietary supplementation restored the tendency for cancer development. In contrast, removal of the ovaries, which eliminated female hormones, did not cause an increase in rate of cancer development. Dietary supplementation of female hormones also failed to have any effect.

“Previously, scientists believed that female hormones may have lent some sort of protection against tumor susceptibility,” said first author Dr. James Amos-Landgraf, assistant professor of veterinary pathobiology at the University of Missouri. “However, by showing that removing testosterone from rats leads to a drastic decrease in colon cancer susceptibility, it appears that male hormones may actually contribute to colon tumor growth rather than female hormones being protective. All women have some level of testosterone in their bodies naturally, but those levels typically are much lower than estrogen and other female hormones. Once women experience menopause and their female hormone levels decrease, their testosterone levels become relatively higher. This corresponds to the time when they begin to experience higher rates of colon cancer and could be a sign of a relationship between testosterone levels and colon tumor growth.”

Related Links:

University of Missouri



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.